Evaluation of Breast Cancer Resistance Protein Function in Hepatobiliary and Renal Excretion Using PET with 11C-SC-62807

@article{Takashima2013EvaluationOB,
  title={Evaluation of Breast Cancer Resistance Protein Function in Hepatobiliary and Renal Excretion Using PET with 11C-SC-62807},
  author={Tadayuki Takashima and Chunyong Wu and Misato Takashima-Hirano and Yumiko Katayama and Yasuhiro Wada and Masaaki Suzuki and Hiroyuki Kusuhara and Yuichi Sugiyama and Yasuyoshi Watanabe},
  journal={The Journal of Nuclear Medicine},
  year={2013},
  volume={54},
  pages={267 - 276}
}
A quantitative PET imaging method was used to assess the in vivo kinetics of hepatobiliary and renal excretion of the breast cancer resistance protein (Bcrp) substrate 11C-SC-62807 in mice. Methods: Serial abdominal PET scans were collected in wild-type and Bcrp knockout (Bcrp–/–) mice after intravenous injection of 11C-SC-62807. Venous blood samples and PET images were obtained at frequent intervals up to 30 min after radiotracer administration. Dynamic PET data were analyzed to determine the… 
Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [11C]Metformin in Mouse
TLDR
Evaluating the function of multidrug and toxin extrusion proteins using 11C-labeled metformin by PET enables the functional analysis of MATEs in the liver and kidneys.
Influence of breast cancer resistance protein and P‐glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice
  • S. Mairinger, V. Zoufal, +8 authors O. Langer
  • Chemistry, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2018
TLDR
Significant effects of the vehicle used for Ko143 formulation on radioactivity distribution to the brain and the liver, as well as on hepatobiliary and urinary excretion of radioactivity are revealed and the power of small‐animal PET to assess the interaction of drug molecules with membrane transporters on a whole body level is illustrated.
Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[11C]Methylpurine in Mice
TLDR
The data suggest that 6-bromo-7-[11C]methylpurine may be useful to assess the activity of MRPs in the kidneys as well as in other organs (brain, lungs), although further work is needed to identify the MRP subtypes involved in the disposition of 6- bromo -7-[ 11C] methylpurine-derived radioactivity.
Practical synthesis of [18F]pitavastatin and evaluation of hepatobiliary transport activity in rats by positron emission tomography.
We developed a practical synthetic method for fluorine-18 (18F)-labeled pitavastatin ([18F]PTV) as a positron emission tomography (PET) tracer to assess hepatobiliary transporter activity and
Hepatocyte-Specific Deletion of EGFR in Mice Reduces Hepatic Abcg2 Transport Activity Measured by [11C]erlotinib and Positron Emission Tomography
TLDR
The data show that EG FR deletion in hepatocytes leads to a reduction in Abcg2-mediated hepatobiliary clearance of a probe substrate accompanied by a shift to renal excretion of the drug, which raises the possibility that EGFR-inhibiting drugs may cause ABCG2- mediated DDIs.
A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography
TLDR
Results suggest that PET imaging with [11C]DPV is an effective tool for quantitatively characterizing the OATP1Bs and MRP2 functions in the human hepatobiliary transport system.
Effect of Rifampicin on the Distribution of [11C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice.
TLDR
The data suggest that a standard clinical dose of rifampicin may exert in vivo a moderate inhibitory effect on hepatic OATP2B1 and that [11C]erlotinib PET in combination with rifampsic in may be used to measure the activity of this/these uptake transporter(s) in vivo.
[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.
  • B. Hosten, R. Boisgard, +6 authors N. Tournier
  • Chemistry, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2013
TLDR
The Bcrp-deficient rat strain, in which no compensatory mechanism or modification of P-gp expression was detected as compared to WT rats, is a suitable model to study BCRp function separately from that of B-gp at the blood-brain barrier.
PET Tracers To Study Clinically Relevant Hepatic Transporters.
TLDR
The present article briefly describes the clinical relevance of hepatic transporters followed by a review of the application of PET imaging for the determination of pharmacokinetic parameters useful to describe the transporter activity and the design, accessibility, and preclinical and clinical applications of available radiotracers.
PET Imaging Analysis with 64Cu in Disulfiram Treatment for Aberrant Copper Biodistribution in Menkes Disease Mouse Model
TLDR
PET studies with 64Cu revealed that disulfiram had significant effects on the copper biodistribution of menkes disease, and the application of 64Cu PET for the treatment of MD and other copper-related disorders may be useful in clinical settings.
...
1
2
3
4
...

References

SHOWING 1-10 OF 32 REFERENCES
PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me
TLDR
PET image analysis with (15R)-11C-TIC-Me is useful for investigating variations in OATP function in the human hepatobiliary transport system and demonstrated that in humans, ( 15R)- 11C- TIC–associated radioactivity is excreted into the bile by organic anion transport systems.
Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds
TLDR
The results suggest that BCRP limits the tissue penetration of xenobiotic compounds in the blood-brain and -testis barriers, but its in vivo importance is also modulated by P-glycoprotein activity.
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
TLDR
The data suggest that the biliary clearance of pitavastatin can be largely accounted for by BCRP in mice and in the case of humans, transcellular transport of pitvastatin was determined in the Madin-Darby canine kidney II cells expressing OATP1B1 and human canalicular efflux transporters.
Evaluation of Limiting Brain Penetration Related to P-glycoprotein and Breast Cancer Resistance Protein Using [11C]GF120918 by PET in Mice
TLDR
Results suggest that brain penetration of [11C]GF120918 is related to modulation of P-gp and BCRP and is limited by two transporters working together.
Use of Tc-99m Mebrofenin as a Clinical Probe to Assess Altered Hepatobiliary Transport: Integration of In Vitro, Pharmacokinetic Modeling, and Simulation Studies
TLDR
MEB may be a useful probe to assess how altered hepatic function at the transport level modulates hepatobiliary drug disposition.
In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
TLDR
In conclusion, [(11)C]gefitinib is a promising PET tracer to evaluate the penetration of gefitinib into the brain by combined therapy with P-gp or BCRP modulators, and into brain tumors.
Positron Emission Tomography Studies Using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin Methyl Ester for the Evaluation of Hepatobiliary Transport
TLDR
It is concluded that PET studies using 15R-[11C]TIC-Me could be useful for in vivo analyses of Mrp2-mediated hepatobiliary transport.
The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.
TLDR
The breast cancer resistance protein [BCRP] belongs to the ATP binding cassette (ABC) family of transmembrane drug transporters and actively extrudes a wide variety of drugs, carcinogens and dietary toxins from cells.
Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice.
TLDR
This is to the authors' knowledge the first demonstration of involvement of Bcrp1 in the renal secretion of organic sulfates, however, taking the results of 4MUS into consideration, the kidneys of human BCRP substrates cannot be accounted for solely by BCrp1, and transporters other than BCRp1 are also involved.
Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans
TLDR
The data indicate that SASP is a candidate probe of BCRP, particularly in its role in intestinal absorption, and the pharmacokinetics of SASP, SP, and N ‐acetylsulfapyridine (AcSP are described simultaneously by nonlinear mixed‐effects modeling (NONMEM) analysis with regard to both gene polymorphisms.
...
1
2
3
4
...